Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

US7074805B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Chih-Hung Lee · Vernon Hills, US
• Erol K. Bayburt · Gurnee, US
• Stanley DiDomenico · Richmond, US
• Irene Drizin · Wadsworth, US
• Arthur Gomtsyan · Vernon Hills, US
• John R. Koenig · Chicago, US
• Richard J. Perner · Gurnee, US
• Robert G. Schmidt · Waukegan, US
• Sean Colm Turner · Ludwigshafen, DE
• Tammie White · Gurnee, US
• Guo Zhu Zheng · Lexington, US

Key dates

• Filing date: Feb 11, 2003
• Grant date: Jul 11, 2006
• Expiry date: Jul 28, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The isoquinoline compounds of formula (I) are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The “R”, “Z” and “L” variables are defined in the disclosure and the “X” variables are defined as follows: